10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended September 30, 2013

or

¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

for the transition period from                      to                     

Commission File Number: 001-35020

INFUSYSTEM HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware	20-3341405
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification No.)

31700 Research Park Drive

Madison Heights, Michigan 48071

(Address of Principal Executive Offices including zip code)

(248) 291-1210

(Registrant’s Telephone Number, Include Area Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Securities Exchange Act.

Large Accelerated Filer	¨	Accelerated Filer	¨
Non-Accelerated Filer	¨ (Do not check if smaller reporting company)	Smaller reporting company	x

Indicated by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act).    Yes  ¨    No  x

As of October 25, 2013, 22,085,031 shares of the registrant’s common stock, par value $0.0001 per share, were outstanding.

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

Index to Form 10-Q

		PAGE
PART I-	FINANCIAL INFORMATION
Item 1.	Financial Statements		3
	Condensed Consolidated Balance Sheets as of September 30, 2013 and December 31, 2012		3
	Condensed Consolidated Statements of Operations and Statements of Comprehensive Income (Loss) for the three and nine months ended September 30, 2013 and 2012		4
	Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2013 and 2012		5
	Notes to Consolidated Financial Statements		6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		12
Item 3.	Quantitative and Qualitative Disclosures About Market Risk		16
Item 4.	Controls and Procedures		16
PART II-	OTHER INFORMATION		17
Item 1.	Legal Proceedings		17
Item 1A.	Risk Factors		17
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		17
Item 3.	Defaults upon Senior Securities		18
Item 4.	Mine Safety Disclosures		18
Item 5.	Other Information		18
Item 6.	Exhibits		19
	Signatures		20

Item 1. Financial Statements

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)	September 30, 2013			December 31, 2012
	(Unaudited)
ASSETS
Current Assets:
Cash and cash equivalents	$	908		$	2,326
Accounts receivable, less allowance for doubtful accounts of $4,178 and $3,136 at September 30, 2013 and December 31, 2012, respectively		9,291			8,511
Inventory		1,343			1,339
Other current assets		625			684
Deferred income taxes		1,986			1,971
Total Current Assets		14,153			14,831
Medical equipment held for sale or rental		2,995			2,626
Medical equipment in rental service, net of accumulated depreciation		14,941			13,071
Property & equipment, net of accumulated depreciation		813			867
Deferred debt issuance costs, net		1,972			2,362
Intangible assets, net		24,075			25,541
Deferred income taxes		17,259			17,806
Other assets		184			419
Total Assets	$	76,392		$	77,523
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts payable	$	4,329		$	2,135
Accounts payable - related party		—			9
Current portion of long-term debt		3,239			3,953
Other current liabilities		2,824			4,098
Total Current Liabilities		10,392			10,195
Long-term debt, net of current portion		24,380			27,315
Total Liabilities		34,772			37,510
Stockholders’ Equity:
Preferred stock, $.0001 par value; authorized 1,000,000 shares; none issued		—			—
Common stock, $.0001 par value; authorized 200,000,000 shares; issued and outstanding 22,088,731 and 22,085,031, respectively, as of September 30, 2013 and 21,990,000 and 21,802,515, respectively, as of December 31, 2012		2			2
Additional paid-in capital		89,544			88,742
Accumulated deficit		(47,926	)		(48,731	)
Total Stockholders’ Equity		41,620			40,013
Total Liabilities and Stockholders’ Equity	$	76,392		$	77,523

See accompanying notes to unaudited consolidated financial statements

3

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND

STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(UNAUDITED)

	Three Months Ended						Nine Months Ended
(in thousands, except share and per share data)	September 30,						September 30,
	2013			2012			2013			2012
Net revenues:
Rentals	$	14,493		$	13,025		$	41,556		$	38,903
Product Sales		1,247			1,150			3,547			3,692
Net revenues		15,740			14,175			45,103			42,595
Cost of revenues:
Cost of revenues — Product, service and supply costs		2,750			2,377			8,174			6,760
Cost of revenues — Pump depreciation and disposals		1,650			1,601			4,836			4,928
Gross profit		11,340			10,197			32,093			30,907
Selling, general and administrative expenses:
Provision for doubtful accounts		1,795			979			4,782			3,119
Amortization of intangibles		648			670			1,972			2,028
Selling and marketing		2,391			2,349			7,281			7,635
General and administrative		4,583			5,278			14,622			17,688
Total sales, general and administrative		9,417			9,276			28,657			30,470
Operating income		1,923			921			3,436			437
Other (expense) income:
Interest expense		(838	)		(971	)		(2,636	)		(2,235	)
Loss on extinguishment of long term debt		—			—			—			(552	)
Other (expense) income		(7	)		(136	)		329			(134	)
Total other expense		(845	)		(1,107	)		(2,307	)		(2,921	)
Income (loss) before income taxes		1,078			(186	)		1,129			(2,484	)
Income tax (expense) benefit		(429	)		219			(324	)		774
Net income (loss)	$	649		$	33		$	805		$	(1,710	)
Net income (loss) per share:
Basic	$	0.03		$	0.00		$	0.04		$	(0.08	)
Diluted	$	0.03		$	0.00		$	0.04		$	(0.08	)
Weighted average shares outstanding:
Basic		21,891,041			21,601,529			21,851,798			21,311,116
Diluted		22,075,532			21,827,365			22,043,998			21,311,116
Comprehensive Income (Loss)
Net income (loss)	$	649		$	33		$	805		$	(1,710	)
Unrealized gain on interest rate swap, net of taxes		—			—			—			1
Reclassification of hedging losses, net of taxes		—			—			—			(111	)
Comprehensive income (loss)	$	649		$	33		$	805		$	(1,820	)

See accompanying notes to unaudited consolidated financial statements

4

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	Nine Months Ended
	September 30,
(in thousands)	2013			2012
NET CASH PROVIDED BY OPERATING ACTIVITIES	$	4,765		$	5,834
INVESTING ACTIVITIES
Purchase of medical equipment and property		(3,396	)		(4,312	)
Proceeds from sale of medical equipment and property		2,808			3,521
NET CASH USED IN INVESTING ACTIVITIES		(588	)		(791	)
FINANCING ACTIVITIES
Principal payments on bank loans, revolving credit facility and capital lease obligations		(27,912	)		(6,747	)
Cash proceeds from bank loans and revolving credit facility		22,395			2,500
Common stock repurchased to satisfy statutory withholding on stock based compensation		(78	)		(131	)
NET CASH USED IN FINANCING ACTIVITIES		(5,595	)		(4,378	)
Net change in cash and cash equivalents		(1,418	)		665
Cash and cash equivalents, beginning of period		2,326			799
Cash and cash equivalents, end of period	$	908		$	1,464

See accompanying notes to unaudited consolidated financial statements

5

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

1. Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies

InfuSystem Holdings, Inc. and Subsidiaries (the “Company”) is a leading provider of infusion pumps and related services. The Company services hospitals, oncology practices and other alternate site healthcare providers. Headquartered in Madison Heights, Michigan, the Company delivers local, field-based customer support, and also operates pump repair Centers of Excellence in Michigan, Kansas, California, and Ontario, Canada.

The accompanying consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly they do not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying consolidated financial statements include all adjustments, composed of normal recurring adjustments, considered necessary by management to fairly state our results of operations, financial position and cash flows. The operating results for the interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in our Annual Report on Form 10-K and Form 10-K/A for the year ended December 31, 2012 (the “2012 Form 10-K”) as filed with the SEC.

The consolidated financial statements are prepared in conformity with U.S. GAAP, which requires the use of estimates, judgments and assumptions that affect the amounts of assets and liabilities at the reporting date and the amounts of revenue and expenses in the periods presented. We believe that the accounting estimates employed are appropriate and the resulting balances are reasonable; however, due to the inherent uncertainties in making estimates, actual results could differ from the original estimates, requiring adjustments to these balances in future periods.

Revised Presentation in the Consolidated Statements

The Company both rents and sells medical equipment. In the first quarter of 2013, it came to management’s attention that based on promulgation through recent comments from the Staff of the Securities and Exchange Commission, greater clarity and consistent classification should be provided in an entity’s financial statements around such assets on the balance sheet and in the statement of cash flows. Specifically, the Staff believed that a company should clearly disclose (i) assets on the balance sheet; and (ii) cash flows when presenting cash flows in relation to, and in consideration of, its predominant source of revenues.

Management believes that the predominant source of revenues and cash flows from this medical equipment is from rentals and that most equipment that the Company has purchased is likely to be rented prior to being sold. The Company first revised its presentation of revenue and cash flows in its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2013 and continues the revised presentation in this report.

While management has concluded that the effect of correcting previous errors in the Company’s financial statements is not material, the Company reclassified certain amounts in its Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2012 to allow for appropriate comparisons between periods presented.

The effect of this reclassification to the Condensed Consolidated Statements of Cash Flows was to both reduce Net cash provided by operating activities and reduce Net cash used in investing activities by $2.4 million for the nine months ended September 30, 2012.

The corrections and reclassifications described above did not affect the Company’s condensed consolidated statements of operations or total cash flows for the nine months ended September 30, 2012.

6

2. Medical Equipment and Property

Medical equipment consisted of the following as of September 30, 2013 and December 31, 2012 (in thousands):

	September 30,			December 31,
	2013			2012
Medical Equipment in rental service	$	37,040		$	34,193
Medical Equipment in rental service - pump reserve		(103	)		(270	)
Accumulated depreciation		(21,996	)		(20,852	)
Medical Equipment in rental service, net of accumulated depreciation
		14,941			13,071
Medical Equipment held for sale or rental		2,995			2,626
Total	$	17,936		$	15,697

Depreciation expense for medical equipment for the three and nine months ended September 30, 2013 was $1.3 million and $3.8 million, respectively, compared to $1.3 million and $4.0 million, respectively, for the same prior year periods. This was recorded in cost of revenues – pump depreciation and disposals.

Depreciation expense for property and equipment for the three months and nine months ended September 30, 2013 was $0.1 million and $0.2 million, respectively, compared to $0.1 million and $0.4 million, respectively, for the same prior year periods. This expense was recorded in general and administrative expenses.

Medical equipment held for sale or rental contains approximately $0.7 million of pre-owned equipment received from a financial institution with such equipment coming off lease. Under the Company’s arrangement with the financial institution, the Company does not pay for the equipment until it is sold. The liability for this equipment is shown in other current liabilities for a similar amount. The Company assumes risk of loss and accounts for the disposition of such equipment as a sale.

3. Goodwill and Intangible Assets

As of June 30, 2012, the goodwill balance was fully impaired with accumulated impairment charges of $64.1 million.

7

Identifiable Intangible Assets

The carrying amount and accumulated amortization of intangible assets as of September 30, 2013 and December 31, 2012 are as follows (in thousands):

	September 30, 2013
	Gross		Accumulated
	Assets		Amortization		Net
Nonamortizable intangible assets
Trade names	$	2,000	$	—	$	2,000
Amortizable intangible assets
Physician and customer relationships		32,866		12,016		20,850
Non-competition agreements		848		576		272
Software		2,153		1,200		953
Total nonamortizable and amortizable intangible assets	$	37,867	$	13,792	$	24,075
	December 31, 2012
	Gross		Accumulated
	Assets		Amortization		Net
Nonamortizable intangible assets
Trade names	$	2,000	$	—	$	2,000
Amortizable intangible assets
Physician and customer relationships		32,866		10,373		22,493
Non-competition agreements		848		441		407
Software		1,647		1,006		641
Total nonamortizable and amortizable intangible assets	$	37,361	$	11,820	$	25,541

Amortization expense for the three and nine months ended September 30, 2013 was $0.6 million and $2.0 million, respectively, compared to $0.7 million and $2.0 million, respectively, for the same prior year periods. Expected annual amortization expense for intangible assets recorded as of September 30, 2013, is as follows (in thousands):

	10/1-										2018 and
	12/31/2013		2014		2015		2016		2017		thereafter
Amortization expense	$	646	$	2,468	$	2,279	$	2,191	$	2,191	$	11,537

4. Derivative Financial Instruments

The Company used derivative instruments to manage interest rate risk and had previously designated an interest rate swap as a cash flow hedge of interest expense related to variable-rate long-term debt. To the extent this hedging relationship was effective; changes in the fair value of the interest rate swap were recorded in Accumulated Other Comprehensive Loss (“AOCL”). Amounts were reclassified from AOCL to interest expense in the period when the hedged forecasted transaction affected earnings. The Company terminated this interest rate swap in December 2012 and had no outstanding derivative contracts as of December 31, 2012 or September 30, 2013.

As of September 30, 2012, the Company had a single interest rate swap liability outstanding with a fair market value of $0.2 million, classified in Derivative Liabilities. This swap had a notional value at September 30, 2012 of $13.4 million. The Company measured the fair value of its interest rate swap using Level 2 fair value measurement inputs which are observable in the market. There were no reclassifications among fair value measurement levels during the period ended September 30, 2012.

8

During the three and nine month periods ended September 30, 2012, changes in the fair value of the derivative and reclassifications from AOCL to earnings were insignificant.

5. Debt

On November 30, 2012, the Company entered into a credit facility with Wells Fargo as Administrative Agent and PennantPark as Lenders. The facility consisted of a $12.0 million Term Loan A (provided by Wells Fargo), a $14.5 million Term Loan B (provided by PennantPark) and a $10.0 million revolving credit facility, all of which mature on November 30, 2016, collectively (the “Credit Facility”). Interest on the term loan is payable at the Company’s choice of LIBOR plus 7.25% (with a LIBOR floor of 2.0%) or the Wells Fargo prime rate plus 6.25% (with a prime rate floor of 3.0%). As of September 30, 2013, interest was payable at the Wells Fargo prime rate plus 6.25%, which equaled 9.50%.

The availability under the revolving Credit Facility is based upon the Company’s eligible accounts receivable and eligible inventory. The Company had revolving loan gross availability of $5.7 million and $6.5 million, respectively, outstanding amounts on the Revolver included $0.6 million and $1.8 million and a reserve amount of $0.1 million on a letter of credit at September 30, 2013, leaving approximately $5.0 million and $4.7 million available under the revolving Credit Facility as of September 30, 2013 and December 31, 2012, respectively.

The Credit Facility is collateralized by substantially all of the Company’s assets and requires the Company to comply with covenants, including but not limited to, financial covenants relating to the satisfaction, on a quarterly and annual basis for the duration of the Credit Facility, of a total leverage ratio, a fixed charge coverage ratio and an annual limit on capital expenditures, including capital leases. As of September 30, 2013, the Company was in compliance with all such covenants and expects to be in compliance over the next 12 months.

In connection with the Credit Facility, the Company has the following covenant obligations for the duration of the facility:

a) The fixed charge coverage ratio is calculated in accordance with the agreement governing the Credit Facility. This covenant was first required to be reported as of March 31, 2013 and has a minimum ratio at that time of 1.25:1. The required ratio varies quarterly for the remainder of the facility duration, from 1.25:1 to 2.00:1.

b) The leverage ratio is calculated in accordance with the agreement governing the Credit Facility. This covenant was first required to be reported as of March 31, 2013 and has a maximum ratio at that time of 2.50:1. The required ratio varies quarterly for the remainder of the facility duration, from 2.50:1 to 1.00:1.

c) The Credit Facility includes an annual limitation on capital expenditures in accordance with the agreement governing the Credit Facility that is $5.5 million for each year ending December 31, 2013 through 2016.

The Company occasionally enters into capital leases to finance the purchase of ambulatory infusion pumps. The pumps are capitalized into medical equipment in rental service at their fair market value, which equals the value of the future minimum lease payments and are depreciated over the useful life of the pumps.

The Company had approximate future maturities of loans and capital leases as of September 30, 2013 as follows (in thousands):

	2013		2014		2015		2016		Total
Term Loans	$	600	$	2,400	$	2,400	$	19,300	$	24,700
Revolver		—		—		—		629		629
Capital Leases		203		852		828		407		2,290
Total	$	803	$	3,252	$	3,228	$	20,336	$	27,619

9

The following is a breakdown of the Company’s current and long-term debt as of September 30, 2013 and December 31, 2012 (in thousands):

	September 30, 2013						December 31, 2012
	Current							Current
	Portion of							Portion of
	Long-Term		Long-					Long-		Long-
	Debt		Term Debt		Total			Term Debt		Term Debt		Total
Term Loans	$	2,400	$	22,300	$	24,700	Term Loans	$	2,400	$	24,100	$	26,500
Revolver		—		629		629	Revolver		—		1,800		1,800
Capital Leases		839		1,451		2,290	Capital Leases		1,553		1,415		2,968
Total	$	3,239	$	24,380	$	27,619	Total	$	3,953	$	27,315	$	31,268

6. Income Taxes

Income tax expense was $0.4 million and $0.3 million for the three and nine months ended September 30, 2013 compared to $0.2 million and $0.8 million, respectively, of tax benefit for the same prior year periods. In computing its income tax provision, the Company estimates its effective income tax rate for the full year and applies that rate to income earned through the reporting period.

Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the three-year period ended September 30, 2013. After adjusting the historical losses for non-recurring items, including the goodwill impairment, legal costs pertaining to events related to the “Concerned Stockholder Group” (as described in our 2012 Form 10-K), severance agreements and sufficient earnings history exists to support the realization of the deferred tax assets. This evidenced ability to generate sufficient taxable income is the basis for the Company’s assessment that the deferred tax assets are more likely than not to be realized.

7. Related Party Transactions

During the three and nine months ended September 30, 2013 and 2012, the Company purchased pumps from Adepto Medical, a company that is controlled by a family member of Mr. Thomas Creal, an Executive Vice-President of the Company. Total purchases during each of the three and nine months ended September 30, 2013 and 2012 were less than $0.1 million, respectively. Outstanding payables associated with the purchases were insignificant as of September 30, 2013 and December 31, 2012. The Company also sold pumps to Adepto. Total sales during the three months and nine months ended September 30, 2013 and 2012 were less than $0.1 million. Outstanding receivables associated with the sales were less than $0.1 million as of September 30, 2013 and December 31, 2012.

The Company also leases buildings from a company partially owned by Mr. Creal. Rent is paid monthly and totals approximately $0.1 million annually.

8. Commitments and Contingencies

The Company is currently involved in legal proceedings arising out of the ordinary course and conduct of our business, the outcomes of which are not determinable at this time. In the normal course of business, the Company has insurance policies with independent insurance carriers to minimize our risk of potential losses. In the Company’s opinion, any liability that might be incurred by us upon the resolution of these claims and lawsuits will not, in the aggregate, have a material effect on the Company’s consolidated financial position, results of operations or cash flows.

10

9. Earnings Per Share

Basic income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Diluted income (loss) per share assumes the issuance of potentially dilutive shares of common stock during the period. The following table reconciles the numerators and denominators of the basic and diluted income (loss) per share computations:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2013		2012		2013		2012
Numerator:
Net income (loss) (in thousands)	$	649	$	33	$	805	$	(1,710	)
Denominator:
Weighted average common shares outstanding:
Basic		21,891,041		21,601,529		21,851,798		21,311,116
Dilutive effect of non-vested awards		184,491		225,836		192,200		—
Diluted		22,075,532		21,827,365		22,043,998		21,311,116
Net income (loss) per share:
Basic	$	0.03	$	0.00	$	0.04	$	(0.08	)
Diluted	$	0.03	$	0.00	$	0.04	$	(0.08	)

For the three and nine months ended September 30, 2013, vested stock options of 1.4 million and 1.3 million, respectively, were not included in the calculation because they would have an anti-dilutive effect. For the same prior year periods, 1.4 million in stock options and 0.7 million in unvested restricted shares, respectively, were not included in the calculation as they would have had an anti-dilutive effect.

During the second quarter of 2012, per the terms of a consulting agreement with former CEO, Mr. Sean McDevitt, the Company terminated 2.0 million shares of common stock potentially issuable under such agreement. Under the consulting agreement, Mr. McDevitt received a consulting fee of $1.0 million, paid in shares of the Company’s common stock. Shares issued to Mr. McDevitt were issued from the Company’s 2007 Stock Incentive Plan, as amended (the “Plan”), valued at the average closing price of a share on the NYSE-MKT on the five trading days preceding the date of such issuance and totaled 0.5 million shares. In addition, the potentially issuable shares of 2.0 million were not part of Company’s 2007 Stock Plan. As these 2.0 million shares were forfeited before the requisite service period was rendered, previously recognized compensation expense of $1.3 million was reversed and recorded as a reduction of general and administrative expense during the three months ended June 30, 2012.

10. Subsequent events

On October 3, 2013, the Company issued a Current Report on Form 8-K that it had received offers to provide external infusion pumps and supplies in all nine of the Metropolitan Statistical Areas (“MSAs”) put out to bid by CMS as part of the announced timetable for Competitive Bidding Round 1 Recompete (“RD1RC”) from August 16, 2012. Since October 3, 2013, the Company has entered into contracts with CMS for these respective MSAs effective January 1, 2014. The impact of the reduced contract price from the current rates in these nine MSAs approximates $250,000 annually based on current volume in those respective MSAs.

11

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

We are a leading provider of infusion pumps and related services. We service hospitals, oncology practices and other alternate site healthcare providers. Headquartered in Madison Heights, Michigan, we deliver local, field-based customer support, and also operate Centers of Excellence in Michigan, Kansas, California, and Ontario, Canada.

We supply electronic ambulatory infusion pumps and associated disposable supply kits to oncology practices, infusion clinics and hospital outpatient chemotherapy clinics. These pumps and supplies are utilized primarily by colorectal cancer patients who receive a standard of care treatment that utilizes continuous chemotherapy infusions delivered via electronic ambulatory infusion pumps. We obtain an assignment of insurance benefits from the patient, bill the insurance company or patient accordingly, and collect payment. We provide pump management services for the pumps and associated disposable supply kits to over 1,800 oncology practices in the United States, and retain title to the pumps during this process.

We sell or rent new and pre-owned pole mounted and ambulatory infusion pumps to, and provide biomedical recertification, maintenance and repair services for, oncology practices as well as other alternate site settings including home care and home infusion providers, skilled nursing facilities, pain centers and others. Additionally we sell, rent, service and repair new and pre-owned infusion pumps and other medical equipment. We also sell a variety of primary and secondary tubing, cassettes, catheters and other disposable items that are utilized with infusion pumps.

On January 3, 2013, we announced that our Board of Directors (the “Board”) had formally ended its assessment of potential strategic alternatives initiated by our prior management in conjunction with the investment banking firm, Houlihan Lokey. In addition, on January 3, 2013, we announced that Janet Skonieczny had been named Chief Operating Officer. For additional information, refer to our Current Report on Form 8-K filed with the SEC on January 3, 2013.

On February 12, 2013, Charles Gillman announced that he would not seek re-election to the Board at the Company’s 2013 annual meeting of stockholders, which has been set for August 29, 2013. For additional information, refer to our Current Report on Form 8-K filed with the SEC on February 12, 2013.

On March 19, 2013, we announced that our Board had appointed Eric K. Steen as our Chief Executive Officer and a member of the Board, effective April 1, 2013 and in connection with Mr. Steen’s appointment, Dilip Singh resigned his position as the Company’s Interim Chief Executive Officer, effective April 1, 2013. Under the terms of the Company’s Employment Agreement with Mr. Singh, dated February 9, 2013, Mr. Singh received a severance payment in the amount of $83,333.33, which was paid to Mr. Singh in March 2013. For additional information, refer to our Current Report on Form 8-K filed with the SEC on March 19, 2013.

On March 30, 2013, Dilip Singh and Charles Gillman each resigned from the Board, effective April 1, 2013. Further, on March 31, 2013, the Board’s Lead Independent Director, John Climaco, resigned from the Board, effective April 1, 2013. In recognition of Mr. Climaco’s service to the Board as Lead Independent Director and Chairman of the Compensation Committee and his leadership of the Company’s CEO search, the Compensation Committee approved a $50,000 payment to Mr. Climaco. In lieu of appointing a new Lead Independent Director to succeed Mr. Climaco, the Board determined that its three independent directors, Messrs. Dreyer, Whitters and Yetter, would coordinate the activities of such Lead Independent Director position. For additional information, refer to our Current Report on Form 8-K filed with the SEC on April 2, 2013.

On May 13, 2013, Ryan Morris, the Executive Chairman of the Board, submitted a written request to the Board for access to limited non-public information for himself and his representatives relating to the exploration of a potential transaction (the “Morris Request”). On May 14, 2013, the Board formed a special committee (the “Special Committee”) to review and be responsible for these matters and considered and responded to the Morris Request (the “Board Response”), indicating that it would allow Mr. Morris, his potential financing sources and other qualified potential bidders a limited period of time and access to the Company’s management team to explore a potential offer for the Company. The Special Committee is comprised of the three independent members of the Board, Messrs. David Dreyer, Joseph Whitters and Wayne Yetter. On May 15, 2013, Mr. Morris provided a written response to the Board Response (the “Morris Response”), and in connection therewith, took a voluntary leave of absence as the Company’s Executive Chairman for the duration of the matters discussed in the letters. During this period, director Wayne Yetter served as the Board’s non-executive Chairman of the Board and Mr. Morris remained on the Board and was compensated as a non-executive director. For additional information, refer to our Current Report on Form 8-K filed with the SEC on May 15, 2013.

On July 1, 2013, we entered into an employment agreement with Jonathan P. Foster, pursuant to which Mr. Foster would continue his service, on a permanent basis, as our Chief Financial Officer effective September 1, 2013. As previously disclosed, Mr. Foster has been serving as Chief Financial Officer since March 16, 2012 under a Consulting Agreement, as amended. For additional information, refer to our Current Report on Form 8-K filed with the SEC on July 8, 2013.

12

On July 17, 2013, Ryan Morris, a member of our Board, delivered a letter to the Special Committee regarding a good faith indication of interest by Meson Capital Partners LP and Mr. Morris to acquire the Company for between $1.85 and $2.00 per share in cash (the “Morris Letter”). On July 18, 2013, the Special Committee considered the Morris Letter and issued a written response (the “Special Committee Response”). The Special Committee believed that the management team, under the leadership of the Company’s new CEO, Eric Steen, will meet the challenges presented by the Center for Medicare and Medicaid Services (“CMS”) competitive bidding and will develop new opportunities for growth creating value for shareholders. The Special Committee continued to believe that the value of the Company was above the proposed offer range of $1.85 to $2.00 per share. However, the Special Committee was prepared to agree to a reasonable period of exclusivity for due diligence and dialogue to better understand and address Mr. Morris’ concerns regarding future risks and to help him to potentially increase the value of his proposal. In addition, the Special Committee requested confirmation of Mr. Morris’ stated financing sources to support his proposal. For additional information, refer to our Current Report on Form 8-K filed with the SEC on July 19, 2013.

On July 31, 2013, the Board issued an Open Letter to Shareholders. In this letter, the Board announced the following: 1) The Special Committee of the Company, after long and careful deliberation and in the best interest of all shareholders, terminated the consideration of a potential sale of the Company; 2) Following thorough discussions with the Special Committee through the Company’s investment banking firm, Houlihan Lokey, Mr. Morris and his potential financing partners did not accept the offer made by the Special Committee in its Special Committee Response; 3) As such, the Board unanimously consented to disband the Special Committee; 4) Effective immediately, Wayne Yetter, while remaining an independent Board member, stepped down as Chairman of the Board and Ryan Morris resumed his position as Executive Chairman. For additional information, refer to our Current Report on Form 8-K filed with the SEC on July 31, 2013.

On August 14, 2013, the Board approved a series of amendments to the Company’s Amended and Restated 2007 Stock Incentive Plan (the “2007 Plan”). First, the amendments provide that the Board’s Compensation Committee will determine the exercise price of any stock options or stock appreciation rights issued under the 2007 Plan, which exercise price must be at or above the current market value for the Company’s common stock on the date of grant. The market value of a Share is defined as the average closing price of the Company’s common stock on its principal stock exchange or, as applicable, the average mean of the closing bid and asked prices quoted on the principal market system for the Company’s stock for the five (5) most recent trading days prior to the date of grant. Second, the 2007 Plan has been amended to specify that, except in connection with a reorganization, share split, recapitalization, merger or other similar corporate event, outstanding stock options or stock appreciation rights may not be repriced nor exchanged for either cash or a substitute award under the 2007 Plan with a lower, or no, exercise price without stockholder approval. Third, the amendments provide that restricted stock awards granted under the 2007 Plan from and after the date of such amendment will reduce the total number of shares remaining available for the Company to grant under the Plan at a rate of two shares per one restricted share granted, and other awards will reduce the number of shares remaining at a rate of one share to one share under the award. Finally, the amendments expressly provide that each 2007 Plan participant is responsible for his/her own tax obligations in respect of awards under the 2007 Plan, and that the Company will not reimburse the participant for any such taxes. Further, the Plan now specifies that no stock options or other 2007 Plan awards may be issued to a participant in order to cover all or any portion of a participant’s exercise price or tax withholding obligations (i.e., “tax gross-ups”) in respect of awards under the 2007 Plan. For additional information and for a complete copy of the 2007 Plan, as amended, refer to our Current Report on Form 8-K filed with the SEC (the “2007 Plan 8-K”) on August 15, 2013.

On October 3, 2013, we issued a Current Report on Form 8-K that we had received offers to provide external infusion pumps and supplies in all nine of the Metropolitan Statistical Areas (“MSAs”) put out to bid by CMS as part of the announced timetable for Competitive Bidding Round 1 Recompete (“RD1RC”) from August 16, 2012. Since October 3, 2013, we have entered into contracts with CMS for these respective MSAs effective January 1, 2014. The impact of the reduced contract price from the current rates in these nine MSAs approximates $250,000 annually based on current volume in those respective MSAs.

During this year, we felt the impact of the sequestration order approved by the President of United States on March 1, 2013, which effects Medicare payments, reducing revenue quarterly by less than $0.1 million since that date. In the absence of any bipartisan agreement in the federal government with respect to the sequestration order generally or relief from sequestration applicable to Medicare payments, this reduction will continue. In addition, the recent federal government shutdown in October 2013 had no impact on our business.

InfuSystem Holdings, Inc. Results of Operations for the three and nine months ended September 30, 2013 compared to the three and nine months ended September 30, 2012

Revenues

        Our revenue for the quarter ended September 30, 2013 was $15.7 million, an 11% increase, compared to $14.2 million for the quarter ended September 30, 2012. This increase was primarily driven by an 11% increase in rental revenue compared to the same period in the prior year. For the nine months ended September 30, 2013 revenue was $45.1 million compared to $42.6 million for the same period ended September 30, 2012, a 6% increase over prior year. Again, this increase was driven by a 7% increase in rental revenue compared to the same period in the prior year. Sales revenue was up 8% from prior year for the third quarter and down approximately 4% year-to-date from prior year comparable periods. Management has been focused on reversing that downward trend in sales which was successful in the third quarter of 2013.

The increase in rental revenues are primarily related to the addition of larger customers, increased penetration into our existing customer accounts, the increase in the colorectal cancer and other cancer patients treated with the Company’s services and the continuation of the revision by a major group of third party payors in their claims processing guidelines. Additionally, since September 30, 2012, the Company has added another 18 plans under contract, the vast majority of which will positively impact revenue. Such strengths are being offset, by a one-time delay in the billings caused by the requirement by certain payors of additional paperwork in the first quarter of 2013 and an increase in unbilled revenue since December 31, 2012. Revenues in the second quarter were impacted significantly due to a delay in processing paperwork both in the field and in-house. Corrections and a reduction in pending billings occurred in the current quarter and further correction and reduction are still expected by year-end 2013. Also during this year, we felt the impact of the sequestration from March 2013, with a reduction of revenue by less than $0.1 million since that date.

Gross Profit

Gross profit for the quarter ended September 30, 2013 was $11.3 million, an increase of 11% compared to $10.2 million for the quarter ended September 30, 2012. Gross profit, as a percentage of revenues, represented 72% for the quarter ended September 30, 2013 and 2012. Gross profit for the nine months ended September 30, 2013 was $32.1 million compared to $30.9 million for the same period in 2012. Gross profit, as a percentage of revenues, represented 71% and 73% for the nine months ended September 30, 2013 and 2012, respectively. The decrease as a percentage of revenue for the nine month period compared to the same prior year period is primarily related to a decrease in rental gross margins from direct pay customers.

13

Provision for Doubtful Accounts

Provision for doubtful accounts for the quarter ended September 30, 2013 and 2012 was $1.8 million and $1.0 million, respectively. The provision for doubtful accounts was 11% of revenues for the quarter ended September 30, 2013 compared to 7% for the same period in the prior year. Provision for doubtful accounts for the nine months ended September 30, 2013 and 2012 was $4.8 million and $3.1 million, respectively, an increase of 53% in 2013. This increase in the provision for doubtful accounts can be mainly attributed to a major group of third party payors that revised their claim processing guidelines at the end of 2012 that affected all durable medical equipment “DME” providers. Prior to the change, DME providers submitted claims to their “home plan” and the claims were processed in-network. Since the change in guidelines, DME providers are now required to submit their claims to the payor in the state where services were initiated. If the DME provider is not a participating provider with that specific payor, the claim is treated as out-of-network and the patient will incur higher costs. Therefore, we must collect a higher portion of reimbursement directly from patients, which creates an increased collection risk. This payor’s association selected us as a preferred provider, which will help us in securing contracts in areas currently out-of-network. As a direct result of this selection, five states have new contracts under this agreement.

Amortization of Intangible Assets

Amortization of intangible assets for the quarter ended September 30, 2013 was $0.6 million, compared to $0.7 million for the same prior year period. Amortization of intangible assets for the nine months ended September 30, 2013 was $2.0 million, consistent with the nine months ended September 30, 2012.

Selling and Marketing Expenses

During the quarter ended September 30, 2013, selling and marketing expenses was $2.4 million, compared to $2.3 million for the same quarter ended September 30, 2012. For the nine months ended September 30, 2013, selling and marketing expenses was $7.3 million, a 5% decrease, compared to $7.6 million for the same period in the prior year. The decrease in selling and marketing expenses for the nine month period was mainly attributed to lower travel, entertainment and salaries and commissions. Selling and marketing expenses during these periods consisted of sales salaries, commissions and associated fringe benefit and payroll-related items, marketing, share-based compensation, travel and entertainment and other miscellaneous expenses.

General and Administrative Expenses

During the quarter ended September 30, 2013, general and administrative (“G&A”) expenses was $4.6 million, a decrease of $0.7 million, or 13%, compared to $5.3 million during the same period in 2012. The decrease was primarily attributed to a reduction in prior year professional fees of $0.3 million pertaining to additional legal and outside service fees as a result of the special meeting and changes in the composition of the Board of Director’s and current year reductions of $0.4 million in other general and administrative cost savings.

During the nine months ended September 30, 2013, general and administrative expenses were $14.6 million compared to $17.7 million for the same nine month period in 2012. The decrease between these periods was primarily related to a reduction in depreciation of $0.4 million in the current year period; prior year costs for professional service and other costs for the Concerned Stockholder Group, which totaled approximately $2.3 million; severance payments for a former CEO amounted to $1.0 million; $0.6 million was recorded during the three months ended March 31, 2012 for retention payments to key employees partially offset by $1.3 million of previously recognized stock compensation expense that was reversed due to the forfeiture and failure to meet the requisite service period.

Interest Expenses

During the quarter ended September 30, 2013, we recorded interest expense of $0.8 million compared to $1.0 million for the quarter ended September 30, 2012. This decrease was mainly attributed to a net decrease of approximately $0.2 million, of which interest expense decreased $0.5 million as a result of costs pertaining to the monthly ticking fee in 2012 equal to 1% of the aggregate amount outstanding partially offset by an increase in interest expense of $0.3 million as a result of our new debt facility. For the nine months ended September 30, 2013, we recorded interest expense of $2.6 million compared to $2.2 million in the same prior year period, which included $0.5 million as a result of costs pertaining to the monthly ticking fee in 2012 equal to 1% of the aggregate amount outstanding. The remaining increase of $0.9 million was primarily related to higher interest rates due to our new credit agreement.

14

Loss on Extinguishment of Long Term Debt

During the prior year nine months ended September 30, 2012, $0.3 million of previously capitalized debt issuance costs and $0.3 million of certain payments made to secure the Fifth Amendment were recognized as a loss on extinguishment of debt.

Other (Expense) Income

Other expense for the quarter ended September 30, 2013 decreased by $0.1 million compared to the same prior period due to the expiration of a tax liability in the prior year period. Other income during the nine months ended September 30, 2013 increased to $0.3 million from an expense of $0.1 million in the same prior year period. This increase of $0.4 million was a result of receiving $0.3 million in proceeds in the current year period when a mutual insurance company we maintained a policy with was acquired and cash payments were disbursed to eligible members and the expiration of a tax liability in the prior year period for $0.1 million.

Income Taxes

During the quarter ended September 30, 2013, we recorded an income tax expense of $0.4 million compared to a tax benefit of $0.2 million for the same period in the prior year. The tax expense was primarily due to the company generating pre-tax income compared to the same period in the prior year. For the nine months ended September 30, 2013, we recorded an income tax expense of $0.3 million compared to a tax benefit of $0.8 million for the same period in the prior year. This was due to our profitability on a year to date basis in 2013 and the aforementioned tax reversal.

Liquidity and Capital Resources

As of September 30, 2013, we had cash or cash equivalents of $0.9 million and $5.0 million of availability on the Credit Facility compared to $2.3 million of cash and cash equivalents and $4.7 million of availability on the Credit Facility at December 31, 2012.

Cash generated by operating activities for the nine months ended September 30, 2013 was $4.8 million compared to $5.8 million for the nine months ended September 30, 2012. Although net income is significantly improved from a year ago, increases in accounts receivable are partially offsetting cash improvement at September 30, 2013 when compared to the prior year.

Cash used in investing activities for the nine months ended September 30, 2013 was $0.6 million compared to $0.8 million for the nine months ended September 30, 2012. The decrease in cash used is primarily related to a decrease in the number of pumps being purchased this year compared to the same period last year. This amount was offset by a decrease in the amount of pumps being sold this year compared to last year and by an increase in the investment in information technology systems by approximately $0.5 million.

Cash used in financing activities for the nine months ended September 30, 2013 was $5.6 million compared to $4.4 million for the nine months ended September 30, 2012. This increase was primarily due to a $1.8 million net increase in principle payments on the term loan, reductions to the revolver balance in addition to payments to retire some older capital leases during 2013.

Availability under the revolving Credit Facility is based upon the Company’s eligible accounts receivable and eligible inventory. The Company had revolving loan gross availability of $5.7 million and $6.5 million, respectively, outstanding amounts on the Revolver included $0.6 million and $1.8 million and a reserve amount of $0.1 million on a letter of credit at September 30, 2013, leaving approximately $5.0 million and $4.7 million available under the revolving Credit Facility as of September 30, 2013 and December 31, 2012, respectively.

Correspondingly, total debt was $27.6 million as of September 30, 2013 compared to $31.3 million as of the end of 2012, a reduction of $3.7 million.

The Credit Facility is collateralized by substantially all of the Company’s assets and requires the Company to comply with covenants, including but not limited to, financial covenants relating to the satisfaction, on a quarterly and annual basis for the duration of the Credit Facility, of a total leverage ratio, a fixed charge coverage ratio and an annual limit on capital expenditures, including capital leases. As of September 30, 2013, the Company was in compliance with all such covenants and expects to be in compliance for the next 12 months.

15

Critical Accounting Policies and Estimates

The consolidated financial statements are prepared in conformity with U.S. GAAP, which require the use of estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses in the periods presented. We believe that the accounting estimates employed are appropriate and resulting balances are reasonable; however, due to inherent uncertainties in making estimates actual results could differ from the original estimates, requiring adjustments to these balances in future periods. The critical accounting estimates that affect the consolidated financial statements and the judgments and assumptions used are consistent with those described in the MD&A section in our 2012 Form 10-K.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

InfuSystem Holdings, Inc. is a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and is not required to provide the information required under this item.

Item 4. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures, (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) that are designed to ensure that information required to be disclosed in our reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal accounting and financial officer), as appropriate, to allow timely decisions regarding required financial disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that a control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, with a company have been detected.

As of the end of the period covered by this Quarterly Report on Form 10-Q, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2013. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that such disclosure controls and procedures as of September 30, 2013, were not effective due to a material weakness in our internal controls related to record-keeping of minutes of the meetings of the Board of Directors and its committees, identified during the fourth quarter of 2012, as described below. Notwithstanding this material weakness, based on additional procedures performed after its discovery, management believes that the financial statements included in this report fairly present in all material respects our financial condition, results of operations, and cash flows for the periods presented.

During the preparation of our Form 10-K for 2012, our management identified a material weakness in the Company’s internal control over financial reporting relating to the timely circulation and approval of minutes of the Board of Directors and its committees and our stock-based compensation calculations for the year ended December 31, 2012. During 2012 a majority of the Company’s Board of Directors and its CEO and CFO, were replaced and, in the transition, timely approval and record-keeping of board minutes were not performed. While minutes were contemporaneously recorded, this material weakness specifically related to the circulation and finalization of approvals of such minutes. Such timely circulation and approvals would have improved the timeliness and preparation of certain accounting analyses and related stock-based compensation calculations. Our management has reassessed its process with regard to Board of Directors and related committee minutes and our stock-based compensation calculations and has taken steps to assure that adequate procedures are in place on a go forward basis to remediate this weakness.

(b) Change in Internal Control Over Financial Reporting

Other than the changes described above, we have made no changes during the three months ended September 30, 2013 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

16

PART II—OTHER INFORMATION

Item 1. Legal Proceedings

We are not involved in any legal proceedings, the outcome of which we believe would be material to our financial condition or results of operations.

Item 1A. Risk Factors

For information regarding factors that could affect our results of operations, financial condition and liquidity, refer to the section titled “Risk Factors” in Part I, Item 1A of our 2012 Form 10-K. Except as noted below, there have been no material changes from the risk factors previously disclosed in our 2012 Form 10-K.

Our business is substantially dependent on third-party reimbursement. Any change in the overall health care reimbursement system may adversely impact our business.

Our revenues are substantially dependent on third-party reimbursement. We are paid directly by private insurers and governmental agencies, often on a fixed fee basis, for the use of continuous infusion equipment and related disposable supplies provided to patients. If the average fees allowable by private insurers or governmental agencies were reduced, the negative impact on revenues could have a material effect on our financial condition, results of operations and cash flows. Also, if amounts owed to us by patients and insurers are reduced or not paid on a timely basis, we may be required to increase our bad debt expense and/or decrease our revenues.

Changes in the health care reimbursement system often create financial incentives and disincentives that encourage or discourage the use of a particular type of product, therapy or clinical procedure. Market acceptance of continuous infusion therapy may be adversely affected by changes or trends within the health care reimbursement system. Changes to the health care reimbursement system that favor other technologies or treatment regimens that reduce reimbursements to providers or treatment facilities, including increasing competitive pressures from home health care and other companies that use our services, may adversely affect our ability to market our services profitably.

On August 16, 2012, the CMS announced the timetable for Competitive Bidding Round 1 Recompete (“RD1RC”), which includes a new product category for external infusion pumps and supplies affecting nine Metropolitan Statistical Areas (“MSAs”). As of the current schedule, any changes in reimbursement associated with RD1RC will not become effective until calendar year 2014. The Company submitted its bid in December 2012. Originally, CMS was to announce single payment amounts and begin the contracting process in the Spring of 2013. During the second quarter of 2013, this schedule, as reflected on CMS’ website, was changed from “Spring 2013” to “Summer 2013”.

On October 3, 2013, the Company announced that it had received offers to provide external infusion pumps and supplies in all nine of the MSAs put out to bid by CMS in RD1RC. Since that date the Company has entered into contracts with CMS for these respective MSAs effective January 1, 2014. The impact of the reduced contract price from the current rates in these nine MSAs approximates $250,000 annually based on current volume in those respective MSAs.

By 2016, CMS is scheduled to fully implement some form of competitive bidding. The impact of this 2016 schedule and RD1RC is not easily identifiable, is unclear at this time, and could, among many factors, negatively impact the Company’s market share, negatively impact business with the Company’s customers and other payors, and significantly reduce revenue, earnings and cash flow.

Any federal government shutdown or changes to sequestration may adversely impact our business.

Our revenues are dependent on private insurers and governmental agencies. The impact of the sequestration order approved in March 2013 effects our Medicare payments. In the absence of any bipartisan agreement in the federal government with respect to the sequestration order or relief from sequestration applicable to Medicare payments, our revenue could be reduced. In addition, any federal government shutdown could also have an adverse impact on our business.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

17

Item 3. Defaults upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

18

Item 6. Exhibits

Exhibits
31.1	Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of the Chief Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2	Certification of the Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

19

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	INFUSYSTEM HOLDINGS, INC.
Date: November 12, 2013	/s/ Jonathan P. Foster
	Jonathan P. Foster
	Chief Financial Officer
	(Principal Financial Officer)

20

EX-31.1

Exhibit 31.1

CERTIFICATION BY PRINCIPAL EXECUTIVE OFFICER

I, Eric Steen, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of InfuSystem Holdings, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 12, 2013	/s/ Eric Steen
	Eric Steen     Chief Executive Officer, President

EX-31.2

Exhibit 31.2

CERTIFICATION BY PRINCIPAL FINANCIAL OFFICER

I, Jonathan P. Foster, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of InfuSystem Holdings, Inc.

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 12, 2013	/s/ Jonathan P. Foster
	Jonathan P. Foster     Chief Financial Officer

EX-32.1

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of InfuSystem Holdings, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The Quarterly Report on Form 10-Q for the quarter ended September 30, 2013 (the “Form 10-Q”) of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended and information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 12, 2013	/s/ Eric Steen
	Eric Steen     Chief Executive Officer, President

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2

Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of InfuSystem Holdings, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The Quarterly Report on Form 10-Q for the quarter ended September 30, 2013 (the “Form 10-Q”) of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended and information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 12, 2013	/s/ Jonathan P. Foster
	Jonathan P. Foster     Chief Financial Officer

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

XML

Medical Equipment and Property (Tables)

9 Months Ended

Sep. 30, 2013

Text Block [Abstract]

Summary of Medical Equipment

Medical equipment consisted of the following as of September 30, 2013 and December 31, 2012 (in thousands):

	September 30,			December 31,
	2013			2012
Medical Equipment in rental service	$	37,040		$	34,193
Medical Equipment in rental service - pump reserve		(103	)		(270	)
Accumulated depreciation		(21,996	)		(20,852	)
Medical Equipment in rental service, net of accumulated depreciation
		14,941			13,071
Medical Equipment held for sale or rental		2,995			2,626
Total	$	17,936		$	15,697

XML

Condensed Consolidated Statements of Operations and Statements of Comprehensive Income (Loss) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Net revenues:
Rentals	$ 14,493	$ 13,025	$ 41,556	$ 38,903
Product Sales	1,247	1,150	3,547	3,692
Net revenues	15,740	14,175	45,103	42,595
Cost of revenues:
Cost of revenues - Product, service and supply costs	2,750	2,377	8,174	6,760
Cost of revenues - Pump depreciation and disposals	1,650	1,601	4,836	4,928
Gross profit	11,340	10,197	32,093	30,907
Selling, general and administrative expenses:
Provision for doubtful accounts	1,795	979	4,782	3,119
Amortization of intangibles	648	670	1,972	2,028
Selling and marketing	2,391	2,349	7,281	7,635
General and administrative	4,583	5,278	14,622	17,688
Total sales, general and administrative	9,417	9,276	28,657	30,470
Operating income	1,923	921	3,436	437
Other (expense) income:
Interest expense	(838)	(971)	(2,636)	(2,235)
Loss on extinguishment of long term debt				(552)
Other (expense) income	(7)	(136)	329	(134)
Total other expense	(845)	(1,107)	(2,307)	(2,921)
Income (loss) before income taxes	1,078	(186)	1,129	(2,484)
Income tax (expense) benefit	(429)	219	(324)	774
Net income (loss)	649	33	805	(1,710)
Net income (loss) per share:
Basic	$ 0.03	$ 0.00	$ 0.04	$ (0.08)
Diluted	$ 0.03	$ 0.00	$ 0.04	$ (0.08)
Weighted average shares outstanding:
Basic	21,891,041	21,601,529	21,851,798	21,311,116
Diluted	22,075,532	21,827,365	22,043,998	21,311,116
Comprehensive Income (Loss)
Net income (loss)	649	33	805	(1,710)
Unrealized gain on interest rate swap, net of taxes				1
Reclassification of hedging losses, net of taxes				(111)
Comprehensive income (loss)	$ 649	$ 33	$ 805	$ (1,820)

XML

Debt

9 Months Ended

Sep. 30, 2013

Debt Disclosure [Abstract]

Debt

5. Debt

On November 30, 2012, the Company entered into a credit facility with Wells Fargo as Administrative Agent and PennantPark as Lenders. The facility consisted of a $12.0 million Term Loan A (provided by Wells Fargo), a $14.5 million Term Loan B (provided by PennantPark) and a $10.0 million revolving credit facility, all of which mature on November 30, 2016, collectively (the “Credit Facility”). Interest on the term loan is payable at the Company’s choice of LIBOR plus 7.25% (with a LIBOR floor of 2.0%) or the Wells Fargo prime rate plus 6.25% (with a prime rate floor of 3.0%). As of September 30, 2013, interest was payable at the Wells Fargo prime rate plus 6.25%, which equaled 9.50%.

The availability under the revolving Credit Facility is based upon the Company’s eligible accounts receivable and eligible inventory. The Company had revolving loan gross availability of $5.7 million and $6.5 million, respectively, outstanding amounts on the Revolver included $0.6 million and $1.8 million and a reserve amount of $0.1 million on a letter of credit at September 30, 2013, leaving approximately $5.0 million and $4.7 million available under the revolving Credit Facility as of September 30, 2013 and December 31, 2012, respectively.

The Credit Facility is collateralized by substantially all of the Company’s assets and requires the Company to comply with covenants, including but not limited to, financial covenants relating to the satisfaction, on a quarterly and annual basis for the duration of the Credit Facility, of a total leverage ratio, a fixed charge coverage ratio and an annual limit on capital expenditures, including capital leases. As of September 30, 2013, the Company was in compliance with all such covenants and expects to be in compliance over the next 12 months.

In connection with the Credit Facility, the Company has the following covenant obligations for the duration of the facility:

a) The fixed charge coverage ratio is calculated in accordance with the agreement governing the Credit Facility. This covenant was first required to be reported as of March 31, 2013 and has a minimum ratio at that time of 1.25:1. The required ratio varies quarterly for the remainder of the facility duration, from 1.25:1 to 2.00:1.

b) The leverage ratio is calculated in accordance with the agreement governing the Credit Facility. This covenant was first required to be reported as of March 31, 2013 and has a maximum ratio at that time of 2.50:1. The required ratio varies quarterly for the remainder of the facility duration, from 2.50:1 to 1.00:1.

c) The Credit Facility includes an annual limitation on capital expenditures in accordance with the agreement governing the Credit Facility that is $5.5 million for each year ending December 31, 2013 through 2016.

The Company occasionally enters into capital leases to finance the purchase of ambulatory infusion pumps. The pumps are capitalized into medical equipment in rental service at their fair market value, which equals the value of the future minimum lease payments and are depreciated over the useful life of the pumps.

The Company had approximate future maturities of loans and capital leases as of September 30, 2013 as follows (in thousands):

	2013		2014		2015		2016		Total
Term Loans	$	600	$	2,400	$	2,400	$	19,300	$	24,700
Revolver		—		—		—		629		629
Capital Leases		203		852		828		407		2,290
Total	$	803	$	3,252	$	3,228	$	20,336	$	27,619

The following is a breakdown of the Company’s current and long-term debt as of September 30, 2013 and December 31, 2012 (in thousands):

	September 30, 2013						December 31, 2012
	Current							Current
	Portion of							Portion of
	Long-Term		Long-					Long-		Long-
	Debt		Term Debt		Total			Term Debt		Term Debt		Total
Term Loans	$	2,400	$	22,300	$	24,700	Term Loans	$	2,400	$	24,100	$	26,500
Revolver		—		629		629	Revolver		—		1,800		1,800
Capital Leases		839		1,451		2,290	Capital Leases		1,553		1,415		2,968
Total	$	3,239	$	24,380	$	27,619	Total	$	3,953	$	27,315	$	31,268

XML

Goodwill and Intangible Assets - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Jun. 30, 2012
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill accumulated impairment charges					$ 64,100,000
Amortization of intangible assets	$ 648,000	$ 670,000	$ 1,972,000	$ 2,028,000

XML

Goodwill and Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2013

Goodwill And Intangible Assets Disclosure [Abstract]

Summary of Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets

The carrying amount and accumulated amortization of intangible assets as of September 30, 2013 and December 31, 2012 are as follows (in thousands):

	September 30, 2013
	Gross		Accumulated
	Assets		Amortization		Net
Nonamortizable intangible assets
Trade names	$	2,000	$	—	$	2,000
Amortizable intangible assets
Physician and customer relationships		32,866		12,016		20,850
Non-competition agreements		848		576		272
Software		2,153		1,200		953
Total nonamortizable and amortizable intangible assets	$	37,867	$	13,792	$	24,075
	December 31, 2012
	Gross		Accumulated
	Assets		Amortization		Net
Nonamortizable intangible assets
Trade names	$	2,000	$	—	$	2,000
Amortizable intangible assets
Physician and customer relationships		32,866		10,373		22,493
Non-competition agreements		848		441		407
Software		1,647		1,006		641
Total nonamortizable and amortizable intangible assets	$	37,361	$	11,820	$	25,541

Schedule of Expected Annual Amortization Expense for Intangible Assets

Expected annual amortization expense for intangible assets recorded as of September 30, 2013, is as follows (in thousands):

	10/1-										2018 and
	12/31/2013		2014		2015		2016		2017		thereafter
Amortization expense	$	646	$	2,468	$	2,279	$	2,191	$	2,191	$	11,537

XML

Derivative Financial Instruments - Additional Information (Detail) (USD $)			9 Months Ended
	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013 Interest Rate Swap [Member]	Sep. 30, 2012 Interest Rate Swap [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative termination period			2012-12
Outstanding derivative contracts	$ 0	$ 0
Interest rate swap liability outstanding				200,000
Interest rate swap agreement, notional value				$ 13,400,000

XML

Goodwill and Intangible Assets - Schedule of Expected Annual Amortization Expense for Intangible Assets (Detail) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2013
Finite Lived Intangible Assets Future Amortization Expense [Abstract]
Amortization expense for remaining fiscal year, 2013	$ 646
Amortization expense, 2014	2,468
Amortization expense, 2015	2,279
Amortization expense, 2016	2,191
Amortization expense, 2017	2,191
Amortization expense, 2018 and thereafter	$ 11,537

XML

Earnings Per Share - Additional Information (Detail) (USD $) In Millions, unless otherwise specified	3 Months Ended		9 Months Ended	3 Months Ended	9 Months Ended	3 Months Ended	9 Months Ended
	Jun. 30, 2012	Sep. 30, 2013 Vested Stock Options [Member]	Sep. 30, 2013 Vested Stock Options [Member]	Sep. 30, 2012 Stock Options [Member]	Sep. 30, 2012 Stock Options [Member]	Sep. 30, 2012 Unvested Restricted Shares [Member]	Sep. 30, 2012 Unvested Restricted Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares with anti-dilutive effect		1.4	1.3	1.4	1.4	0.7	0.7
Forfeiture of potentially issuable common stock	2.0
Common stock issued in lieu of consulting fee, value	$ 1.0
Common stock issued in lieu of consulting fee, shares	0.5
Reversal of compensation expense	$ 1.3

XML

Income Taxes - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Income Tax Disclosure [Abstract]
Income tax (expense) income	$ (429)	$ 219	$ (324)	$ 774
Period at which cumulative loss incurred			3 years

XML

Goodwill and Intangible Assets - Summary of Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets (Detail) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Indefinite Lived And Finite Lived Intangible Assets [Line Items]
Total nonamortizable and amortizable intangible assets, Gross Assets	$ 37,867	$ 37,361
Total nonamortizable and amortizable intangible assets, Accumulated Amortization	13,792	11,820
Total nonamortizable and amortizable intangible assets, Net	24,075	25,541
Physician and Customer Relationships [Member]
Indefinite Lived And Finite Lived Intangible Assets [Line Items]
Amortizable intangible assets, Gross Assets	32,866	32,866
Amortizable intangible assets, Accumulated Amortization	12,016	10,373
Amortizable intangible assets, Net	20,850	22,493
Non-Competition Agreements [Member]
Indefinite Lived And Finite Lived Intangible Assets [Line Items]
Amortizable intangible assets, Gross Assets	848	848
Amortizable intangible assets, Accumulated Amortization	576	441
Amortizable intangible assets, Net	272	407
Software [Member]
Indefinite Lived And Finite Lived Intangible Assets [Line Items]
Amortizable intangible assets, Gross Assets	2,153	1,647
Amortizable intangible assets, Accumulated Amortization	1,200	1,006
Amortizable intangible assets, Net	953	641
Trade Names [Member]
Indefinite Lived And Finite Lived Intangible Assets [Line Items]
Nonamortizable intangible assets	$ 2,000	$ 2,000

XML

Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2013

Accounting Policies [Abstract]

Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies

1. Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies

InfuSystem Holdings, Inc. and Subsidiaries (the “Company”) is a leading provider of infusion pumps and related services. The Company services hospitals, oncology practices and other alternate site healthcare providers. Headquartered in Madison Heights, Michigan, the Company delivers local, field-based customer support, and also operates pump repair Centers of Excellence in Michigan, Kansas, California, and Ontario, Canada.

The accompanying consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly they do not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying consolidated financial statements include all adjustments, composed of normal recurring adjustments, considered necessary by management to fairly state our results of operations, financial position and cash flows. The operating results for the interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in our Annual Report on Form 10-K and Form 10-K/A for the year ended December 31, 2012 (the “2012 Form 10-K”) as filed with the SEC.

The consolidated financial statements are prepared in conformity with U.S. GAAP, which requires the use of estimates, judgments and assumptions that affect the amounts of assets and liabilities at the reporting date and the amounts of revenue and expenses in the periods presented. We believe that the accounting estimates employed are appropriate and the resulting balances are reasonable; however, due to the inherent uncertainties in making estimates, actual results could differ from the original estimates, requiring adjustments to these balances in future periods.

Revised Presentation in the Consolidated Statements

The Company both rents and sells medical equipment. In the first quarter of 2013, it came to management’s attention that based on promulgation through recent comments from the Staff of the Securities and Exchange Commission, greater clarity and consistent classification should be provided in an entity’s financial statements around such assets on the balance sheet and in the statement of cash flows. Specifically, the Staff believed that a company should clearly disclose (i) assets on the balance sheet; and (ii) cash flows when presenting cash flows in relation to, and in consideration of, its predominant source of revenues.

Management believes that the predominant source of revenues and cash flows from this medical equipment is from rentals and that most equipment that the Company has purchased is likely to be rented prior to being sold. The Company first revised its presentation of revenue and cash flows in its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2013 and continues the revised presentation in this report.

While management has concluded that the effect of correcting previous errors in the Company’s financial statements is not material, the Company reclassified certain amounts in its Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2012 to allow for appropriate comparisons between periods presented.

The effect of this reclassification to the Condensed Consolidated Statements of Cash Flows was to both reduce Net cash provided by operating activities and reduce Net cash used in investing activities by $2.4 million for the nine months ended September 30, 2012.

The corrections and reclassifications described above did not affect the Company’s condensed consolidated statements of operations or total cash flows for the nine months ended September 30, 2012.

XML

Goodwill and Intangible Assets

9 Months Ended

Sep. 30, 2013

Goodwill And Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

3. Goodwill and Intangible Assets

As of June 30, 2012, the goodwill balance was fully impaired with accumulated impairment charges of $64.1 million.

Identifiable Intangible Assets

The carrying amount and accumulated amortization of intangible assets as of September 30, 2013 and December 31, 2012 are as follows (in thousands):

	September 30, 2013
	Gross		Accumulated
	Assets		Amortization		Net
Nonamortizable intangible assets
Trade names	$	2,000	$	—	$	2,000
Amortizable intangible assets
Physician and customer relationships		32,866		12,016		20,850
Non-competition agreements		848		576		272
Software		2,153		1,200		953
Total nonamortizable and amortizable intangible assets	$	37,867	$	13,792	$	24,075
	December 31, 2012
	Gross		Accumulated
	Assets		Amortization		Net
Nonamortizable intangible assets
Trade names	$	2,000	$	—	$	2,000
Amortizable intangible assets
Physician and customer relationships		32,866		10,373		22,493
Non-competition agreements		848		441		407
Software		1,647		1,006		641
Total nonamortizable and amortizable intangible assets	$	37,361	$	11,820	$	25,541

Amortization expense for the three and nine months ended September 30, 2013 was $0.6 million and $2.0 million, respectively, compared to $0.7 million and $2.0 million, respectively, for the same prior year periods. Expected annual amortization expense for intangible assets recorded as of September 30, 2013, is as follows (in thousands):

	10/1-										2018 and
	12/31/2013		2014		2015		2016		2017		thereafter
Amortization expense	$	646	$	2,468	$	2,279	$	2,191	$	2,191	$	11,537

XML

Income Taxes

9 Months Ended

Sep. 30, 2013

Income Tax Disclosure [Abstract]

Income Taxes

6. Income Taxes

Income tax expense was $0.4 million and $0.3 million for the three and nine months ended September 30, 2013 compared to $0.2 million and $0.8 million, respectively, of tax benefit for the same prior year periods. In computing its income tax provision, the Company estimates its effective income tax rate for the full year and applies that rate to income earned through the reporting period.

Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the three-year period ended September 30, 2013. After adjusting the historical losses for non-recurring items, including the goodwill impairment, legal costs pertaining to events related to the “Concerned Stockholder Group” (as described in our 2012 Form 10-K), severance agreements and sufficient earnings history exists to support the realization of the deferred tax assets. This evidenced ability to generate sufficient taxable income is the basis for the Company’s assessment that the deferred tax assets are more likely than not to be realized.

XML

Derivative Financial Instruments

9 Months Ended

Sep. 30, 2013

Derivative Instruments And Hedging Activities Disclosure [Abstract]

Derivative Financial Instruments

4. Derivative Financial Instruments

The Company used derivative instruments to manage interest rate risk and had previously designated an interest rate swap as a cash flow hedge of interest expense related to variable-rate long-term debt. To the extent this hedging relationship was effective; changes in the fair value of the interest rate swap were recorded in Accumulated Other Comprehensive Loss (“AOCL”). Amounts were reclassified from AOCL to interest expense in the period when the hedged forecasted transaction affected earnings. The Company terminated this interest rate swap in December 2012 and had no outstanding derivative contracts as of December 31, 2012 or September 30, 2013.

As of September 30, 2012, the Company had a single interest rate swap liability outstanding with a fair market value of $0.2 million, classified in Derivative Liabilities. This swap had a notional value at September 30, 2012 of $13.4 million. The Company measured the fair value of its interest rate swap using Level 2 fair value measurement inputs which are observable in the market. There were no reclassifications among fair value measurement levels during the period ended September 30, 2012.

During the three and nine month periods ended September 30, 2012, changes in the fair value of the derivative and reclassifications from AOCL to earnings were insignificant.

XML

Debt - Additional Information (Detail) (USD $) In Millions, unless otherwise specified	1 Months Ended		1 Months Ended		3 Months Ended
	Nov. 30, 2012	Sep. 30, 2013	Nov. 30, 2012 LIBOR [Member]	Nov. 30, 2012 Prime Rate [Member]	Mar. 31, 2013 Credit Facility [Member]	Mar. 31, 2013 Credit Facility [Member] Minimum [Member]	Mar. 31, 2013 Credit Facility [Member] Maximum [Member]	Nov. 30, 2012 Term Loan A [Member]	Nov. 30, 2012 Term Loan B [Member]	Sep. 30, 2013 Revolving Credit Facility [Member]	Dec. 31, 2012 Revolving Credit Facility [Member]	Nov. 30, 2012 Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Line of credit facility								$ 12.0	$ 14.5	$ 5.7	$ 6.5	$ 10.0
Credit facility, maturity date	Nov. 30, 2016
Interest on the term loans, description	LIBOR plus 7.25% (with a LIBOR floor of 2.0%) or the Wells Fargo prime rate plus 6.25% (with a prime rate floor of 3.0%)
Interest rate on term loan			7.25%	6.25%
Debt instrument floor rate			2.00%	3.00%
Interest rate		9.50%
Revolving loan amounts outstanding										0.6	1.8
Revolving credit facility available										5.0	4.7
Reserve amount on letter of credit										0.1
Minimum fixed charge coverage ratio					1.25
Fixed charge coverage ratio for the remainder period						1.25	2.00
Maximum leverage ratio					2.50
Leverage ratio for remainder period						1.00	2.50
Credit facility subject to limitation on capital expenditures in year one		5.5
Credit facility subject to limitation on capital expenditures in year two		5.5
Credit facility subject to limitation on capital expenditures in year three		5.5
Credit facility subject to limitation on capital expenditures in year four		$ 5.5

XML

Related Party Transactions - Additional Information (Detail) (USD $) In Millions, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Related Party Transactions [Abstract]
Total purchases	$ 0.1	$ 0.1	$ 0.1	$ 0.1
Total sales	0.1	0.1	0.1	0.1
Outstanding receivables	0.1		0.1		0.1
Rent paid			$ 0.1

XML

Condensed Consolidated Balance Sheets (Parenthetical) (USD $) In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Statement Of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 4,178	$ 3,136
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	22,088,731	21,990,000
Common stock, shares outstanding	22,085,031	21,802,515

XML

Earnings Per Share

9 Months Ended

Sep. 30, 2013

Earnings Per Share [Abstract]

Earnings Per Share

9. Earnings Per Share

Basic income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Diluted income (loss) per share assumes the issuance of potentially dilutive shares of common stock during the period. The following table reconciles the numerators and denominators of the basic and diluted income (loss) per share computations:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2013		2012		2013		2012
Numerator:
Net income (loss) (in thousands)	$	649	$	33	$	805	$	(1,710	)
Denominator:
Weighted average common shares outstanding:
Basic		21,891,041		21,601,529		21,851,798		21,311,116
Dilutive effect of non-vested awards		184,491		225,836		192,200		—
Diluted		22,075,532		21,827,365		22,043,998		21,311,116
Net income (loss) per share:
Basic	$	0.03	$	0.00	$	0.04	$	(0.08	)
Diluted	$	0.03	$	0.00	$	0.04	$	(0.08	)

For the three and nine months ended September 30, 2013, vested stock options of 1.4 million and 1.3 million, respectively, were not included in the calculation because they would have an anti-dilutive effect. For the same prior year periods, 1.4 million in stock options and 0.7 million in unvested restricted shares, respectively, were not included in the calculation as they would have had an anti-dilutive effect.

During the second quarter of 2012, per the terms of a consulting agreement with former CEO, Mr. Sean McDevitt, the Company terminated 2.0 million shares of common stock potentially issuable under such agreement. Under the consulting agreement, Mr. McDevitt received a consulting fee of $1.0 million, paid in shares of the Company’s common stock. Shares issued to Mr. McDevitt were issued from the Company’s 2007 Stock Incentive Plan, as amended (the “Plan”), valued at the average closing price of a share on the NYSE-MKT on the five trading days preceding the date of such issuance and totaled 0.5 million shares. In addition, the potentially issuable shares of 2.0 million were not part of Company’s 2007 Stock Plan. As these 2.0 million shares were forfeited before the requisite service period was rendered, previously recognized compensation expense of $1.3 million was reversed and recorded as a reduction of general and administrative expense during the three months ended June 30, 2012.

XML

Condensed Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Statement Of Cash Flows [Abstract]
NET CASH PROVIDED BY OPERATING ACTIVITIES	$ 4,765	$ 5,834
INVESTING ACTIVITIES
Purchase of medical equipment and property	(3,396)	(4,312)
Proceeds from sale of medical equipment and property	2,808	3,521
NET CASH USED IN INVESTING ACTIVITIES	(588)	(791)
FINANCING ACTIVITIES
Principal payments on bank loans, revolving credit facility and capital lease obligations	(27,912)	(6,747)
Cash proceeds from bank loans and revolving credit facility	22,395	2,500
Common stock repurchased to satisfy statutory withholding on stock based compensation	(78)	(131)
NET CASH USED IN FINANCING ACTIVITIES	(5,595)	(4,378)
Net change in cash and cash equivalents	(1,418)	665
Cash and cash equivalents, beginning of period	2,326	799
Cash and cash equivalents, end of period	$ 908	$ 1,464

XML

Condensed Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Current Assets:
Cash and cash equivalents	$ 908	$ 2,326
Accounts receivable, less allowance for doubtful accounts of $4,178 and $3,136 at September 30, 2013 and December 31, 2012, respectively	9,291	8,511
Inventory	1,343	1,339
Other current assets	625	684
Deferred income taxes	1,986	1,971
Total Current Assets	14,153	14,831
Medical equipment held for sale or rental	2,995	2,626
Medical equipment in rental service, net of accumulated depreciation	14,941	13,071
Property & equipment, net of accumulated depreciation	813	867
Deferred debt issuance costs, net	1,972	2,362
Intangible assets, net	24,075	25,541
Deferred income taxes	17,259	17,806
Other assets	184	419
Total Assets	76,392	77,523
Current Liabilities:
Accounts payable	4,329	2,135
Accounts payable - related party		9
Current portion of long-term debt	3,239	3,953
Other current liabilities	2,824	4,098
Total Current Liabilities	10,392	10,195
Long-term debt, net of current portion	24,380	27,315
Total Liabilities	34,772	37,510
Stockholders' Equity:
Preferred stock, $.0001 par value; authorized 1,000,000 shares; none issued
Common stock, $.0001 par value; authorized 200,000,000 shares; issued and outstanding 22,088,731 and 22,085,031, respectively, as of September 30, 2013 and 21,990,000 and 21,802,515, respectively, as of December 31, 2012	2	2
Additional paid-in capital	89,544	88,742
Accumulated deficit	(47,926)	(48,731)
Total Stockholders' Equity	41,620	40,013
Total Liabilities and Stockholders' Equity	$ 76,392	$ 77,523

XML

Debt - Summary of Future Maturities of Loans and Capital Leases (Detail) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Line of Credit Facility [Line Items]
Remainder of 2013	$ 803
2014	3,252
2015	3,228
2016	20,336
Total	27,619	31,268
Term Loans [Member]
Line of Credit Facility [Line Items]
Remainder of 2013	600
2014	2,400
2015	2,400
2016	19,300
Total	24,700	26,500
Revolver [Member]
Line of Credit Facility [Line Items]
Remainder of 2013
2014
2015
2016	629
Total	629	1,800
Capital Leases [Member]
Line of Credit Facility [Line Items]
Remainder of 2013	203
2014	852
2015	828
2016	407
Total	$ 2,290	$ 2,968

XML

Medical Equipment and Property - Additional Information (Detail) (USD $) In Millions, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Property, Plant and Equipment [Line Items]
Depreciation expense for medical equipment recorded in cost of revenues - pump depreciation and disposals	$ 1.3	$ 1.3	$ 3.8	$ 4.0
Depreciation expense for property and equipment recorded in general and administrative expenses	0.1	0.1	0.2	0.4
Pre-Owned Equipment [Member]
Property, Plant and Equipment [Line Items]
Medical equipment held for sale or rental - financial institution	$ 0.7		$ 0.7

XML

Subsequent Events - Additional Information (Detail) (USD $)	1 Months Ended	0 Months Ended
	Oct. 31, 2013	Oct. 03, 2013 Subsequent Event [Member] Areas
Subsequent Event [Line Items]
Number of Metropolitan Statistical Areas		9
Reduction of contract price from current rates in MSAs	$ 250,000

XML

Commitments and Contingencies

9 Months Ended

Sep. 30, 2013

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

8. Commitments and Contingencies

The Company is currently involved in legal proceedings arising out of the ordinary course and conduct of our business, the outcomes of which are not determinable at this time. In the normal course of business, the Company has insurance policies with independent insurance carriers to minimize our risk of potential losses. In the Company’s opinion, any liability that might be incurred by us upon the resolution of these claims and lawsuits will not, in the aggregate, have a material effect on the Company’s consolidated financial position, results of operations or cash flows.

XML

Debt - Summary of Company's Current and Long-Term Debt (Detail) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Line of Credit Facility [Line Items]
Current portion of long-term debt	$ 3,239	$ 3,953
Long-Term Debt	24,380	27,315
Total	27,619	31,268
Term Loans [Member]
Line of Credit Facility [Line Items]
Current portion of long-term debt	2,400	2,400
Long-Term Debt	22,300	24,100
Total	24,700	26,500
Revolver [Member]
Line of Credit Facility [Line Items]
Current portion of long-term debt
Long-Term Debt	629	1,800
Total	629	1,800
Capital Leases [Member]
Line of Credit Facility [Line Items]
Current portion of long-term debt	839	1,553
Long-Term Debt	1,451	1,415
Total	$ 2,290	$ 2,968

XML

Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2013

Accounting Policies [Abstract]

Revised Presentation in the Consolidated Statements

Revised Presentation in the Consolidated Statements

The Company both rents and sells medical equipment. In the first quarter of 2013, it came to management’s attention that based on promulgation through recent comments from the Staff of the Securities and Exchange Commission, greater clarity and consistent classification should be provided in an entity’s financial statements around such assets on the balance sheet and in the statement of cash flows. Specifically, the Staff believed that a company should clearly disclose (i) assets on the balance sheet; and (ii) cash flows when presenting cash flows in relation to, and in consideration of, its predominant source of revenues.

Management believes that the predominant source of revenues and cash flows from this medical equipment is from rentals and that most equipment that the Company has purchased is likely to be rented prior to being sold. The Company first revised its presentation of revenue and cash flows in its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2013 and continues the revised presentation in this report.

While management has concluded that the effect of correcting previous errors in the Company’s financial statements is not material, the Company reclassified certain amounts in its Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2012 to allow for appropriate comparisons between periods presented.

The effect of this reclassification to the Condensed Consolidated Statements of Cash Flows was to both reduce Net cash provided by operating activities and reduce Net cash used in investing activities by $2.4 million for the nine months ended September 30, 2012.

The corrections and reclassifications described above did not affect the Company’s condensed consolidated statements of operations or total cash flows for the nine months ended September 30, 2012.

XML

Related Party Transactions

9 Months Ended

Sep. 30, 2013

Related Party Transactions [Abstract]

Related Party Transactions

7. Related Party Transactions

During the three and nine months ended September 30, 2013 and 2012, the Company purchased pumps from Adepto Medical, a company that is controlled by a family member of Mr. Thomas Creal, an Executive Vice-President of the Company. Total purchases during each of the three and nine months ended September 30, 2013 and 2012 were less than $0.1 million, respectively. Outstanding payables associated with the purchases were insignificant as of September 30, 2013 and December 31, 2012. The Company also sold pumps to Adepto. Total sales during the three months and nine months ended September 30, 2013 and 2012 were less than $0.1 million. Outstanding receivables associated with the sales were less than $0.1 million as of September 30, 2013 and December 31, 2012.

The Company also leases buildings from a company partially owned by Mr. Creal. Rent is paid monthly and totals approximately $0.1 million annually.

XML

Medical Equipment and Property

9 Months Ended

Sep. 30, 2013

Text Block [Abstract]

Medical Equipment and Property

2. Medical Equipment and Property

Medical equipment consisted of the following as of September 30, 2013 and December 31, 2012 (in thousands):

	September 30,			December 31,
	2013			2012
Medical Equipment in rental service	$	37,040		$	34,193
Medical Equipment in rental service - pump reserve		(103	)		(270	)
Accumulated depreciation		(21,996	)		(20,852	)
Medical Equipment in rental service, net of accumulated depreciation
		14,941			13,071
Medical Equipment held for sale or rental		2,995			2,626
Total	$	17,936		$	15,697

Depreciation expense for medical equipment for the three and nine months ended September 30, 2013 was $1.3 million and $3.8 million, respectively, compared to $1.3 million and $4.0 million, respectively, for the same prior year periods. This was recorded in cost of revenues – pump depreciation and disposals.

Depreciation expense for property and equipment for the three months and nine months ended September 30, 2013 was $0.1 million and $0.2 million, respectively, compared to $0.1 million and $0.4 million, respectively, for the same prior year periods. This expense was recorded in general and administrative expenses.

Medical equipment held for sale or rental contains approximately $0.7 million of pre-owned equipment received from a financial institution with such equipment coming off lease. Under the Company’s arrangement with the financial institution, the Company does not pay for the equipment until it is sold. The liability for this equipment is shown in other current liabilities for a similar amount. The Company assumes risk of loss and accounts for the disposition of such equipment as a sale.

XML

Earnings Per Share - Numerators and Denominators of Basic and Diluted Income (Loss) Per Share (Detail) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Numerator:
Net income (loss)	$ 649	$ 33	$ 805	$ (1,710)
Weighted average common shares outstanding:
Basic	21,891,041	21,601,529	21,851,798	21,311,116
Dilutive effect of non-vested awards	184,491	225,836	192,200
Diluted	22,075,532	21,827,365	22,043,998	21,311,116
Net income (loss) per share:
Basic	$ 0.03	$ 0.00	$ 0.04	$ (0.08)
Diluted	$ 0.03	$ 0.00	$ 0.04	$ (0.08)

XML

Debt (Tables)

9 Months Ended

Sep. 30, 2013

Debt Disclosure [Abstract]

Summary of Future Maturities of Loans and Capital Leases

The Company had approximate future maturities of loans and capital leases as of September 30, 2013 as follows (in thousands):

	2013		2014		2015		2016		Total
Term Loans	$	600	$	2,400	$	2,400	$	19,300	$	24,700
Revolver		—		—		—		629		629
Capital Leases		203		852		828		407		2,290
Total	$	803	$	3,252	$	3,228	$	20,336	$	27,619

Summary of Company's Current and Long-Term Debt

The following is a breakdown of the Company’s current and long-term debt as of September 30, 2013 and December 31, 2012 (in thousands):

	September 30, 2013						December 31, 2012
	Current							Current
	Portion of							Portion of
	Long-Term		Long-					Long-		Long-
	Debt		Term Debt		Total			Term Debt		Term Debt		Total
Term Loans	$	2,400	$	22,300	$	24,700	Term Loans	$	2,400	$	24,100	$	26,500
Revolver		—		629		629	Revolver		—		1,800		1,800
Capital Leases		839		1,451		2,290	Capital Leases		1,553		1,415		2,968
Total	$	3,239	$	24,380	$	27,619	Total	$	3,953	$	27,315	$	31,268

XML

Subsequent events

9 Months Ended

Sep. 30, 2013

Subsequent Events [Abstract]

Subsequent events

10. Subsequent events

On October 3, 2013, the Company issued a Current Report on Form 8-K that it had received offers to provide external infusion pumps and supplies in all nine of the Metropolitan Statistical Areas (“MSAs”) put out to bid by CMS as part of the announced timetable for Competitive Bidding Round 1 Recompete (“RD1RC”) from August 16, 2012. Since October 3, 2013, the Company has entered into contracts with CMS for these respective MSAs effective January 1, 2014. The impact of the reduced contract price from the current rates in these nine MSAs approximates $250,000 annually based on current volume in those respective MSAs.

XML

Medical Equipment and Property - Summary of Medical Equipment (Detail) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Medical Equipment And Property [Abstract]
Medical Equipment in rental service	$ 37,040	$ 34,193
Medical Equipment in rental service - pump reserve	(103)	(270)
Accumulated depreciation	(21,996)	(20,852)
Medical Equipment in rental service, net of accumulated depreciation	14,941	13,071
Medical equipment held for sale or rental	2,995	2,626
Total	$ 17,936	$ 15,697

XML

Earnings Per Share (Tables)

9 Months Ended

Sep. 30, 2013

Earnings Per Share [Abstract]

Numerators and Denominators of Basic and Diluted Income (Loss) Per Share

The following table reconciles the numerators and denominators of the basic and diluted income (loss) per share computations:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2013		2012		2013		2012
Numerator:
Net income (loss) (in thousands)	$	649	$	33	$	805	$	(1,710	)
Denominator:
Weighted average common shares outstanding:
Basic		21,891,041		21,601,529		21,851,798		21,311,116
Dilutive effect of non-vested awards		184,491		225,836		192,200		—
Diluted		22,075,532		21,827,365		22,043,998		21,311,116
Net income (loss) per share:
Basic	$	0.03	$	0.00	$	0.04	$	(0.08	)
Diluted	$	0.03	$	0.00	$	0.04	$	(0.08	)

XML

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Oct. 25, 2013
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q3
Entity Registrant Name	InfuSystem Holdings, Inc
Entity Central Index Key	0001337013
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		22,085,031

XML

Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies - Additional Information (Detail) (USD $) In Millions, unless otherwise specified	9 Months Ended
	Sep. 30, 2012
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Reduction of Net cash provided by operating and investing activity	$ 2.4